

## **REMARKS**

The specification has been amended to correct a spelling error in the title. The claims have been amended without prejudice or disclaimer to manage the claims fees. Claims 2 and 7 have been canceled. Claims 1, 3-6, and 8-11 have been amended, and claims 12 and 13 have been added. These claims are based on disclosure at page 7, lines 16-19 (“... antibodies that can decrease the inhibitory effect of serum with a high antiphospholipid antibody titre on the binding of Annexin V to endothelial cells ....”), page 7, line 11 (“... anti-aPAF antibodies ....”), page 7, lines 9-11 (“... anti-IgG antibodies ....”), and page 7, lines 4-7 (“... intravenous immunoglobulin preparation from pooled plasma ....”). Thus, claims 1, 3-6 and 8-13 are pending.

Applicants retain the right pursue the subject matter as originally claimed in future applications. The filing fee has been calculated after amendment of the claims by the preliminary amendment. No new matter is added by entry of this preliminary amendment.

It is believed that no fee is due with this communication, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed document, the Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski Deposit Account No. 50-1212/EPCL:015US.

The examiner is invited to contact the undersigned attorney with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: August 21, 2007